A pill to treat Covid-19: 'We're talking about a return to, maybe, normal life'

Once sidelined for lack of interest, oral antivirals to treat coronavirus infections are now a subject of fierce competition and funding. In June, the Biden administration announced it had agreed to obtain about 1.7 million treatment courses of Merck's molnupiravir, at a cost of $1.2 billion, if the product receives emergency authorization or full approval. The same month, the administration said it would invest $3.2 billion in the Antiviral Program for Pandemics, which aims to develop antivirals for the covid crisis and beyond, Dieffenbach said.

https://www.msn.com/en-ca/health/medical/a-pill-to-treat-covid-19-were-talking-about-a-return-to-maybe-normal-life/ar-AAOSro2?ocid=ientp